AU7034691A - Lipoprotein signal peptide fused to antigenic polypeptides - Google Patents

Lipoprotein signal peptide fused to antigenic polypeptides

Info

Publication number
AU7034691A
AU7034691A AU70346/91A AU7034691A AU7034691A AU 7034691 A AU7034691 A AU 7034691A AU 70346/91 A AU70346/91 A AU 70346/91A AU 7034691 A AU7034691 A AU 7034691A AU 7034691 A AU7034691 A AU 7034691A
Authority
AU
Australia
Prior art keywords
signal peptide
antigenic polypeptides
peptide fused
lipoprotein signal
lipoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU70346/91A
Other languages
English (en)
Inventor
Peter Lau
Clement Rioux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
Canada Minister of Natural Resources
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canada Minister of Natural Resources, National Research Council of Canada filed Critical Canada Minister of Natural Resources
Publication of AU7034691A publication Critical patent/AU7034691A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU70346/91A 1989-12-26 1990-12-27 Lipoprotein signal peptide fused to antigenic polypeptides Abandoned AU7034691A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45647389A 1989-12-26 1989-12-26
US456473 1989-12-26

Publications (1)

Publication Number Publication Date
AU7034691A true AU7034691A (en) 1991-07-24

Family

ID=23812898

Family Applications (1)

Application Number Title Priority Date Filing Date
AU70346/91A Abandoned AU7034691A (en) 1989-12-26 1990-12-27 Lipoprotein signal peptide fused to antigenic polypeptides

Country Status (4)

Country Link
EP (1) EP0510018A1 (de)
AU (1) AU7034691A (de)
CA (1) CA2032914A1 (de)
WO (1) WO1991009952A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
AU681572B2 (en) * 1991-10-21 1997-09-04 Med Immune, Inc. Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins
FR2708622B1 (fr) * 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US6335018B1 (en) 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6440425B1 (en) * 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
ZA964896B (en) 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
EP1741718A3 (de) * 1995-06-07 2007-03-28 Sanofi Pasteur Inc. Expression von lipoproteinen
US6251405B1 (en) * 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
CN108135181A (zh) * 2015-09-04 2018-06-08 斯克利普斯研究院 定新型抗生素及相关组合物的方法
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
EP3935159A1 (de) 2019-03-08 2022-01-12 Obsidian Therapeutics, Inc. Menschliche carboanhydrase-2-zusammensetzungen und verfahren zur abstimmbaren regulierung
US20220267398A1 (en) 2019-06-12 2022-08-25 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US20220259284A1 (en) 2019-06-12 2022-08-18 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US20220348937A1 (en) 2019-09-06 2022-11-03 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation

Also Published As

Publication number Publication date
EP0510018A1 (de) 1992-10-28
WO1991009952A1 (en) 1991-07-11
CA2032914A1 (en) 1991-06-27

Similar Documents

Publication Publication Date Title
AU570004B2 (en) Antigenic modification of peptides
IL94243A0 (en) Fusion polypeptide and its preparation
AU7034691A (en) Lipoprotein signal peptide fused to antigenic polypeptides
ZA901737B (en) Peptides
AU3977589A (en) Novel peptides
AU1957288A (en) Synthetic peptides related to hiv-env proteins
AU4927390A (en) Fusion proteins
GB8920357D0 (en) Peptides
GB8817160D0 (en) Novel proteins
AU5407190A (en) Peptides having novel polar n-terminal groups
IL93447A0 (en) Milled proteins
AU2684388A (en) Peptides acting to influence the mammalian pituitary
AU6938987A (en) Lymphocyte-activating polypeptides
GB2248839B (en) Process for the separation of proteins or polypeptides
ZA901695B (en) Recombinant protein receptor
GB8905606D0 (en) Peptides
AU3253689A (en) A process for the preparation of proteins which start with n-terminal proline
GB9025320D0 (en) N-terminal modification of proteins
EP0470520A3 (en) Process for the preparation of peptides or polypeptides in a cell-free translation system
IE881482L (en) Recombinant htlv-iii proteins
AU6087990A (en) Psycho-pharmacological peptides
GB8913991D0 (en) Recombinant hybrid proteins
IE891280L (en) Recombinant antibodies
GB8921172D0 (en) Proteins
GB8820923D0 (en) Peptide sequence & antibody thereto